Blood Reviews
Volume 23, Issue 3 , Pages 129-135 , May 2009

Does antithrombotic therapy improve survival in cancer patients?

  • Moya S. Cunningham

      Affiliations

    • Academic Unit of Clinical and Molecular Oncology, Institute of Molecular Medicine, Trinity College Dublin, Ireland
    • ,
  • Roger J.S. Preston

      Affiliations

    • Haemostasis Research Group, Institute of Molecular Medicine, Trinity Health Centre, St. James’s Hospital, Trinity College Dublin, Ireland
    • ,
  • James S. O’Donnell

      Affiliations

    • Haemostasis Research Group, Institute of Molecular Medicine, Trinity Health Centre, St. James’s Hospital, Trinity College Dublin, Ireland
    • National Centre for Hereditary Coagulation Disorders, St. James’s Hospital, James’s Street, Dublin, Ireland
    • Corresponding Author InformationCorresponding author. Address: Haemostasis Research Group, Institute of Molecular Medicine, Trinity Health Centre, St. James’s Hospital, Trinity College Dublin, Ireland. Tel.: +353 1 416 2141; fax: +353 1 410 3570.

References 

  1. Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case–control study. Arch Intern Med. 2000;160:809–815
  2. Heit JA, O’Fallon WM, Petterson TM, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med. 2002;162:1245–1248
  3. Bick RL. Alterations of hemostasis associated with malignancy: etiology, pathophysiology, diagnosis and management. Semin Thromb Hemost. 1978;5:1–26
  4. Lee AY. Management of thrombosis in cancer: primary prevention and secondary prophylaxis. Br J Haematol. 2005;128:291–302
  5. Ambrus JL, Ambrus CM, Mink IB, Pickren JW. Causes of death in cancer patients. J Med. 1975;6:61–64
  6. Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes. Circulation. 2003;107:I17–I21
  7. Prandoni P, Lensing AW, Buller HR, et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med. 1992;327:1128–1133
  8. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore). 1999;78:285–291
  9. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343:1846–1850
  10. Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008;133:454S–545S
  11. Weitz JI. Low-molecular-weight heparins. N Engl J Med. 1997;337:688–698
  12. Harrison L, McGinnis J, Crowther M, Ginsberg J, Hirsh J. Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin. Arch Intern Med. 1998;158:2001–2003
  13. Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008;133:340S–380S
  14. Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007;25:5490–5505
  15. Carr KM, Rabinowitz I. Physician compliance with warfarin prophylaxis for central venous catheters in patients with solid tumors. J Clin Oncol. 2000;18:3665–3667
  16. Hutten BA, Prins MH, Gent M, et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol. 2000;18:3078–3083
  17. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100:3484–3488
  18. Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146–153
  19. Deitcher SR, Kessler CM, Merli G, et al. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost. 2006;12:389–396
  20. Hull RD, et al. North American Fragmin Trial Investigators Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs. in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. Arch Intern Med. 2000;160:2208–2215
  21. Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med. 2002;162:1729–1735
  22. Baglin TP, Keeling DM, Watson HG. Guidelines on oral anticoagulation (warfarin): 3rd edition – 2005 update. Br J Haematol. 2006;132:277–285
  23. Wagman LD, Baird MF, Bennett CL, et al. Venous thromboembolic disease. Clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2006;4:838–869
  24. Goldenberg N, Kahn SR, Solymoss S. Markers of coagulation and angiogenesis in cancer-associated venous thromboembolism. J Clin Oncol. 2003;21:4194–4199
  25. Lip GY, Chin BS, Blann AD. Cancer and the prothrombotic state. Lancet Oncol. 2002;3:27–34
  26. Prandoni P, Piccioli A, Girolami A. Cancer and venous thromboembolism: an overview. Haematologica. 1999;84:437–445
  27. Winter PC. The pathogenesis of venous thromboembolism in cancer: emerging links with tumour biology. Hematol Oncol. 2006;24:126–133
  28. Tilley R, Mackman N. Tissue factor in hemostasis and thrombosis. Semin Thromb Hemost. 2006;32:5–10
  29. Kakkar AK, DeRuvo N, Chinswangwatanakul V, Tebbutt S, Williamson RC. Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor. Lancet. 1995;346:1004–1005
  30. Karti SS, Ovali E, Ozgur O, et al. Induction of apoptosis and inhibition of growth of human hepatoma HepG2 cells by heparin. Hepatogastroenterology. 2003;50:1864–1866
  31. Palumbo JS, Degen JL. Hemostatic factors in tumor biology. J Pediatr Hematol Oncol. 2000;22:281–287
  32. Palumbo JS. Mechanisms linking tumor cell-associated procoagulant function to tumor dissemination. Semin Thromb Hemost. 2008;34:154–160
  33. Beer JH, Haeberli A, Vogt A, et al. Coagulation markers predict survival in cancer patients. Thromb Haemost. 2002;88:745–749
  34. Gallus AS. Prevention of post-operative deep leg vein thrombosis in patients with cancer. Thromb Haemost. 1997;78:126–132
  35. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest. 2001;119:132S–175S
  36. Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989;320:479–484
  37. Elliott MA, Wolf RC, Hook CC, et al. Thromboembolism in adults with acute lymphoblastic leukemia during induction with l-asparaginase-containing multi-agent regimens: incidence, risk factors, and possible role of antithrombin. Leuk Lymphoma. 2004;45:1545–1549
  38. Marx GM, Steer CB, Harper P, et al. Unexpected serious toxicity with chemotherapy and antiangiogenic combinations: time to take stock!. J Clin Oncol. 2002;20:1446–1448
  39. Zangari M, Anaissie E, Barlogie B, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood. 2001;98:1614–1615
  40. Cunningham MS, White B, Hollywood D, O’Donnell J. Primary thromboprophylaxis for cancer patients with central venous catheters – a reappraisal of the evidence. Br J Cancer. 2006;94:189–194
  41. Belting M, Dorrell MI, Sandgren S, et al. Regulation of angiogenesis by tissue factor cytoplasmic domain signaling. Nat Med. 2004;10:502–509
  42. Agostino D, Cliffton EE, Girolami A. Effect of prolonged coumadin treatment on the production of pulmonary metastases in the rat. Cancer. 1966;19:284–288
  43. Ryan JJ, Ketcham AS, Wexler H. Warfarin treatment of mice bearing autochthonous tumors: effect on spontaneous metastases. Science. 1968;162:1493–1494
  44. Lione A, Bosmann HB. The inhibitory effect of heparin and warfarin treatments on the intravascular survival of B16 melanoma cells in syngeneic C57 mice. Cell Biol Int Rep. 1978;2:81–86
  45. Brown JM. A study of the mechanism by which anticoagulation with warfarin inhibits blood-borne metastases. Cancer Res. 1973;33:1217–1224
  46. Higashi H, Heidelberger C. Lack of effect of warfarin (NSC-59813) alone or in combination with 5-fluorouracil (NSC-19893) on primary and metastatic L1210 leukemia and adenocarcinoma 755. Cancer Chemother Rep. 1971;55:29–33
  47. Chahinian AP, Propert KJ, Ware JH, et al. A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. J Clin Oncol. 1989;7:993–1002
  48. Maurer LH, Herndon JE, Hollis DR, et al. Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study. J Clin Oncol. 1997;15:3378–3387
  49. Zacharski LR, Henderson WG, Rickles FR, et al. Effect of warfarin on survival in small cell carcinoma of the lung. Veterans Administration Study No. 75. JAMA. 1981;245:831–835
  50. Zacharski LR, Henderson WG, Rickles FR, et al. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study No. 75. Cancer. 1984;53:2046–2052
  51. Blumentals WA, Foulis PR, Schwartz SW, Mason TJ. Does warfarin therapy influence the risk of bladder cancer?. Thromb Haemost. 2004;91:801–805
  52. Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of anticoagulation trial. N Engl J Med. 2000;342:1953–1958
  53. Taliani MR, Agnelli G, Prandoni P, et al. Incidence of cancer after a first episode of idiopathic venous thromboembolism treated with 3 months or 1 year of oral anticoagulation. J Thromb Haemost. 2003;1:1730–1733
  54. Akl EA, Kamath G, Yosuico V, et al. Thromboprophylaxis for patients with cancer and central venous catheters: a systematic review and a meta-analysis. Cancer. 2008;112:2483–2492
  55. Lebeau B, Chastang C, Brechot JM, et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. “Petites Cellules” Group. Cancer. 1994;74:38–45
  56. Altinbas M, Coskun HS, Er O, et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost. 2004;2:1266–1271
  57. Kakkar AK, Levine MN, Kadziola Z, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol. 2004;22:1944–1948
  58. Klerk CP, Smorenburg SM, Otten HM, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol. 2005;23:2130–2135
  59. Sideras K, Schaefer PL, Okuno SH, et al. Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc. 2006;81:758–767
  60. Akl EA, van Doormaal FF, Barba M, et al. Parenteral anticoagulation may prolong the survival of patients with limited small cell lung cancer: a Cochrane systematic review. J Exp Clin Cancer Res. 2008;27:4
  61. White RH, Ginsberg JS. Low-molecular-weight heparins: are they all the same?. Br J Haematol. 2003;121:12–20
  62. Degen JL, Palumbo JS. Mechanisms linking hemostatic factors to tumor growth in mice. Pathophysiol Haemost Thromb. 2003;33(Suppl. 1):31–35
  63. Falanga A, Marchetti M. Heparin in tumor progression and metastatic dissemination. Semin Thromb Hemost. 2007;33:688–694
  64. Palumbo JS, Talmage KE, Massari JV, et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood. 2005;105:178–185
  65. Palumbo JS, Kombrinck KW, Drew AF, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood. 2000;96:3302–3309
  66. Palumbo JS, Degen JL. Fibrinogen and tumor cell metastasis. Haemostasis. 2001;31(Suppl. 1):11–15
  67. Bobek V, Kovarik J. Antitumor and antimetastatic effect of warfarin and heparins. Biomed Pharmacother. 2004;58:213–219
  68. Hostettler N, Naggi A, Torri G, et al. P-selectin- and heparanase-dependent antimetastatic activity of non-anticoagulant heparins. FASEB J. 2007;21:3562–3572
  69. Smorenburg SM, Van Noorden CJ. The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev. 2001;53:93–105
  70. Borsig L, Wong R, Feramisco J, et al. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci USA. 2001;98:3352–3357
  71. Jayson GC, Gallagher JT. Heparin oligosaccharides: inhibitors of the biological activity of bFGF on Caco-2 cells. Br J Cancer. 1997;75:9–16
  72. Marchetti M, Vignoli A, Russo L, et al. Endothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparin. Thromb Res. 2008;121:637–645
  73. Balzarotti M, Fontana F, Marras C, et al. In vitro study of low molecular weight heparin effect on cell growth and cell invasion in primary cell cultures of high-grade gliomas. Oncol Res. 2006;16:245–250
  74. Li HL, Ye KH, Zhang HW, et al. Effect of heparin on apoptosis in human nasopharyngeal carcinoma CNE2 cells. Cell Res. 2001;11:311–315
  75. Parish CR, Freeman C, Brown KJ, Francis DJ, Cowden WB. Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity. Cancer Res. 1999;59:3433–3441

PII: S0268-960X(08)00080-5

doi: 10.1016/j.blre.2008.10.002

Blood Reviews
Volume 23, Issue 3 , Pages 129-135 , May 2009

Article Tools